Research programme: endopeptidase inhibitors - American Life Science Pharmaceuticals

Drug Profile

Research programme: endopeptidase inhibitors - American Life Science Pharmaceuticals

Alternative Names: acetyl-L-leucyl-L-valyl-L-lysinal-aldehyde; ALP 496; ALSP Next generation compounds; CA 074Me; E 64d

Latest Information Update: 02 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator American Life Science Pharmaceuticals; Columbia University; University of Illinois at Chicago
  • Class Neuropeptides; Small molecules
  • Mechanism of Action Amyloid precursor protein secretase modulators; Cathepsin B inhibitors; Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Brain injuries

Most Recent Events

  • 29 Jan 2016 Preclinical development is ongoing in USA
  • 15 Sep 2015 American Life Science Pharmaceuticals establishes CRADA with Walter Reed Army Institute of Research for the development of cathepsin-based therapeutics in Brain Injuries
  • 02 Feb 2015 American Life Science Pharmaceuticals in-licenses Neurodegenerative disorder therapeutics from Columbia University and University of Illinois at Chicago
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top